发明名称 T-cell vaccination with viral vectors via mechanical epidermal disruption
摘要 Attenuated, replication-deficient viruses such as vaccinia viruses are used to deliver an exogenous viral, bacterial, parastic or tumor antigen to an epidermal tissue such as the skin, lungs or gastrointestinal tract, which has been mechanically disrupted, in an amount effective to elicit or stimulate a cell mediated immune response. The epidermis may be mechanically disrupted prior to, at the same time, or immediately after the administration of the vaccine. The vaccine can be used to induce immunity against a pathogen, such as a virus, bacteria, or parasite, or against a cancer in a subject that has or is at risk of developing cancer.
申请公布号 US9416371(B2) 申请公布日期 2016.08.16
申请号 US201414165126 申请日期 2014.01.27
申请人 TremRx, Inc. 发明人 Kupper Thomas S.;Liu Luzheng Lisa;Clark Rachel A.
分类号 C12N15/86;A61K39/12;A61K38/17;A61K38/18;A61K38/19;A61K38/20;A61K39/285;A61K39/00 主分类号 C12N15/86
代理机构 Pabst Patent Group LLP 代理人 Pabst Patent Group LLP
主权项 1. A method for inducing or stimulating a T cell mediated immune response to an exogenous T cell antigen in epithelial tissues of a human subject comprising administering to the epithelial tissue of the subject a live, modified, non-replicating poxvirus expressing the antigen to cause a local infection in the epithelial skin tissue in an amount sufficient to cause the infected cells to express viral proteins, the exogenous T cell antigen and inflammatory factors and stimulate a T cell immune response in the lymph nodes to the exogenous T cell antigen, wherein the live, modified, poxvirus expressing the antigen is administered to epithelial skin tissue that is disrupted to penetrate the stratum corneum without penetrating the entire epidermis.
地址 Boston MA US